Major pharmaceutical companies such as Dr. Reddy's, Biocon and Intas Biopharmaceuticals (IBPL) from India, along with 3SBio from China, have created a strong position for themselves in the emerging biosimilars market, with a number of biosimilar products launched and generating revenue. Companies such as Cipla, Ranbaxy and Lupin have shown interest in the opportunities offered by the emerging biosimilars market and have taken initiatives to enter the market through strategic consolidations and biosimilars R&D. However, the regulatory guidelines for biosimilars require strengthening in most emerging economies in order to meet international standards and increase coverage to include all types of biosimilars.
- Data and analysis on biosimilars markets in emerging economies - Market forecasts for the emerging biosimilars market to 2018, with regional market forecasts for India and China. - Key drivers and restraints that have had a significant impact on the emerging biosimilars market. - The regulatory environment for biosimilars in India, China and other emerging economies. - Analysis of key companies in the industry, with profiles of major companies in the emerging biosimilars market. - Analysis of the biosimilars R&D pipeline across various stages of development. - Key M&A activities, licensing agreements and co-developments that have taken place in the emerging biosimilar market Reasons to buy - Make more informed business decisions from the insightful and in-depth analysis of the emerging biosimilars market and the factors that shape it. - Identify key areas of deal making through an understanding of the deals landscape in the emerging biosimilars market. - Build effective strategies to launch pipeline products by identifying potential target regions. - Identify prominent companies from emerging economies and their capabilities for collaborations.